Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GCK | P35557 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14687925 | 0.86 | RAB9A (0.52) | LMNAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL14701824 | 0.85 | GCK (0.45) | PKMGCKKMT2AMEN1 | |
| SCHEMBL29788823 | 0.83 | GCK (0.56) | LMNAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL2551479 | 0.83 | GCK (0.56) | LMNAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL2556127 | 0.83 | GCK (0.44) | PKMGCKKMT2AMEN1 | |
| SCHEMBL2551785 | 0.78 | NOS3 (0.41) | LMNAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12283891 | 0.73 | GCK (0.43) | PKMGCKKMT2AMEN1 | |
| SCHEMBL2558200 | 0.73 | NPC1 (0.48) | LMNAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL1987461 | 0.72 | HCK (0.53) | LMNAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL29083255 | 0.72 | MEN1 (0.45) | LMNAALDH1A1POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| EP-2556068-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | LMNA 3242/4885ALDH1A1 1479/4885POLB 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.